Ambroxol Hydrochloride and Its Impact on Clinical Recovery in Infants With Otitis Media

This study assessed the clinical efficacy of ambroxol hydrochloride in treating infantile secretory otitis media (SOM). Ninety-two infants diagnosed with SOM were randomly assigned to an experimental group, receiving conventional treatment plus ambroxol hydrochloride, or a control group, receiving routine care alone. Outcomes included treatment effectiveness, inflammatory markers (SIL-2R and IL-8), pure tone air-bone gap, tympanic pressure, and incidence of adverse reactions. The experimental group showed significantly higher treatment effectiveness (P < 0.05), elevated SIL-2R and IL-8 levels (P < 0.05), reduced air-bone gap (P < 0.05), improved tympanic pressure (P < 0.05), and fewer adverse reactions (P < 0.05) compared to controls. These findings suggest that ambroxol hydrochloride enhances both clinical outcomes and safety in the management of infantile SOM, supporting its use in clinical practice.